Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

JAK Inhibition Reduces CD25 high CD27 + FOXp3 + T Regulatory Cells and Causes a Silencing Of T Effector Cells In Patients With Myeloproliferative Neoplasms Whilst Promoting a TH17 Phenotype

Clodagh Keohane, MD, Shahram Y Kordasti, MD, PhD, Thomas Seidl, Pilar Perez Abellan, Nicholas Shaun B. Thomas, PhD, Ghulam J Mufti, FRCP, FRCPath, Claire N Harrison, DM, FRCP, FRCPath, Donal McLornan, MD, PhD

Blood (2013) 122 (21): 4092.

https://doi.org/10.1182/blood.V122.21.4092.4092

Published: 2013

Journal Articles

Vascular Endothelial Cells Promote the Viability of CLL Cells Via the up-Regulation of Bcl-2 and Bcl-XL

Andrea G S. Buggins, Ph.D., Piers EM Patten, BSc, MRCP, MRCPath, Satyen H Gohil, MBBS, B.Sc., Ghulam J Mufti, FRCP, FRCPath, M.D., Nicholas Shaun B. Thomas, PhD, Stephen Devereux, FRCP, FRCPath, Ph.D.

Blood (2008) 112 (11): 357.

https://doi.org/10.1182/blood.V112.11.357.357

Published: 2008

Journal Articles

Early and Sustained Response to Azacytidine in High-Risk MDS Patients with Monosomy 7 Correlates with Increased Apoptosis and Not CDKN2B Demethylation.

Kavita K. Raj, MD, Alison M. John, PhD, Aloysius Ho, MD, Nicholas Shaun B. Thomas, PhD, Ghulam J. Mufti, MD

Blood (2005) 106 (11): 2530.

https://doi.org/10.1182/blood.V106.11.2530.2530

Published: 2005

Journal Articles

Serum Protein Profiling Distinguishes BCR-ABL+ CML from Normal and Neutrophilia Cases.

Azim M. Mohamedali, PhD, Satyaji Sahu, MD, Nicholas Shaun B. Thomas, PhD, Ghulam J. Mufti, MD

Blood (2005) 106 (11): 4871.

https://doi.org/10.1182/blood.V106.11.4871.4871

Published: 2005

Journal Articles

5-Azacytidine in the Treatment of High Risk Myelodysplastic Syndromes: Clinical Response Can Occur without Demethylation of the CDKN2B , CDKN1A or TP73 Gene Promoters.

Kavita Raj, MD, Alison John, PhD, Aloysius Ho, MD, Nicholas Shaun B. Thomas, PhD, Ghulam J. Mufti, MD

Blood (2004) 104 (11): 2369.

https://doi.org/10.1182/blood.V104.11.2369.2369

Published: 2004

NARROW

JAK Inhibition Reduces CD25 high CD27 + FOXp3 + T Regulatory Cells and Causes a Silencing Of T Effector Cells In Patients With Myeloproliferative Neoplasms Whilst Promoting a TH17 Phenotype

Vascular Endothelial Cells Promote the Viability of CLL Cells Via the up-Regulation of Bcl-2 and Bcl-XL

Early and Sustained Response to Azacytidine in High-Risk MDS Patients with Monosomy 7 Correlates with Increased Apoptosis and Not CDKN2B Demethylation.

Serum Protein Profiling Distinguishes BCR-ABL+ CML from Normal and Neutrophilia Cases.

5-Azacytidine in the Treatment of High Risk Myelodysplastic Syndromes: Clinical Response Can Occur without Demethylation of the CDKN2B , CDKN1A or TP73 Gene Promoters.

Email alerts

ASH Publications

American Society of Hematology

JAK Inhibition Reduces CD25 high CD27 + FOXp3 + T Regulatory Cells and Causes a Silencing Of T Effector Cells In Patients With Myeloproliferative Neoplasms Whilst Promoting a TH17 Phenotype

Vascular Endothelial Cells Promote the Viability of CLL Cells Via the up-Regulation of Bcl-2 and Bcl-XL

Early and Sustained Response to Azacytidine in High-Risk MDS Patients with Monosomy 7 Correlates with Increased Apoptosis and Not CDKN2B Demethylation.

Serum Protein Profiling Distinguishes BCR-ABL+ CML from Normal and Neutrophilia Cases.

5-Azacytidine in the Treatment of High Risk Myelodysplastic Syndromes: Clinical Response Can Occur without Demethylation of the CDKN2B , CDKN1A or TP73 Gene Promoters.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only